SpringerLink
Log in

The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review

  • Statin Drugs (H.-.C Diener, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In this review, we discuss the evidence supporting the effects of statins on mast cells (MCs) in atherosclerosis and their molecular mechanism of action.

Recent Findings

Statins or HMG-CoA reductase inhibitors are known for their lipid-lowering properties and are widely used in the prevention and treatment of cardiovascular diseases. There is growing evidence that statins have an inhibitory effect on MCs, which contributes to the pleiotropic effect of statins in various diseases. MCs are one of the crucial effectors of the immune system which play an essential role in the pathogenesis of multiple disorders. Recent studies have shown that MCs are involved in the development of atherosclerotic plaques. MCs secrete various inflammatory cytokines (IL-6, IL4, TNF-α, and IFNγ) and inflammatory mediators (histamine, tryptase, proteoglycans) after activation by various stimulants. This, in turn, will exacerbate atherosclerosis. Statins suppress the activation of MCs via IgE inhibition which leads to inhibition of inflammatory mediators and cytokines which are involved in the development and progression of atherosclerosis.

Summary

In kee** with this evidence presented here, MCs can be considered as one of the therapeutic targets for statins in the treatment of atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Wilcock A, Bahri R, Bulfone-Paus S, Arkwright PD. Mast cell disorders: from infancy to maturity. Allergy. 2019;74(1):53–63.

    Article  PubMed  Google Scholar 

  2. Lagraauw HM (2015) Stress-induced modulation of the innate immune system in cardiovascular disease. Biopharmacy division, Leiden Academic Center for Drug Research (LACDR …,

  3. Kritikou E, Kuiper J, Kovanen PT, Bot I. The impact of mast cells on cardiovascular diseases. Eur J Pharmacol. 2016;778:103–15.

    Article  CAS  PubMed  Google Scholar 

  4. Bachelet I, Levi-Schaffer F, Mekori YA. Mast cells: not only in allergy. Immunol Allergy Clin. 2006;26(3):407–25.

    Article  Google Scholar 

  5. Krauth M, Majlesi Y, Sonneck K, Samorapoompichit P, Ghannadan M, Hauswirth A, et al. Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells. Allergy. 2006;61(3):281–8.

  6. Meyer N, Zenclussen AC. Mast cells—good guys with a bad image? Am J Reprod Immunol. 2018;80(4):e13002.

    Article  PubMed  Google Scholar 

  7. Ringvall M, Rönnberg E, Wernersson S, Duelli A, Henningsson F, Åbrink M, et al. Serotonin and histamine storage in mast cell secretory granules is dependent on serglycin proteoglycan. J Allergy Clin Immunol. 2008;121(4):1020–6.

  8. Krystel-Whittemore M, Dileepan KN, Wood JG. Mast cell: a multi-functional master cell. Front Immunol. 2016;6:620.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Roy A. Mast cells as sentinels: role of serglycin and mast cell proteases in infection and inflammation: Acta Universitatis Upsaliensis; 2012.

  10. Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. Nat Rev Immunol. 2014;14(7):478–94.

    Article  CAS  PubMed  Google Scholar 

  11. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125(2):S73–80.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Moon TC, Befus AD, Kulka M. Mast cell mediators: their differential release and the secretory pathways involved. Front Immunol. 2014;5:569.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Ashmole I, Bradding P. Ion channels regulating mast cell biology. Clin Exp Allergy. 2013;43(5):491–502.

    Article  CAS  PubMed  Google Scholar 

  14. Yeganeh B, Wiechec E, Ande SR, Sharma P, Moghadam AR, Post M, et al. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther. 2014;143(1):87–110.

  15. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, García FA, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. Jama. 2016;316(19):1997–2007.

  16. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.

  17. Parizadeh SM, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S, et al. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids. 2011;46(4):333–40.

  18. Yaribeygi H, Faghihi N, Mohammadi MT, Sahebkar A. Effects of atorvastatin on myocardial oxidative and nitrosative stress in diabetic rats. Comp Clin Pathol. 2018;27(3):691–7.

    Article  CAS  Google Scholar 

  19. Dulak J, Józkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005;5(8):579–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta-analysis of controlled trials. Autoimmun Rev. 2016;15(4):344–53.

    Article  CAS  PubMed  Google Scholar 

  21. Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, et al. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194–208.

  22. Bianconi V, Sahebkar A, Banach M, Pirro M. Statins, haemostatic factors and thrombotic risk. Curr Opin Cardiol. 2017;32(4):460–6.

    Article  PubMed  Google Scholar 

  23. Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GY, et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Thromb Haemost. 2016;115(03):520–32.

  24. Sahebkar A, Catena C, Ray KK, Vallejo-Vaz AJ, Reiner Ž, Sechi LA, et al. Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. Thromb Haemost. 2016;116(07):162–71.

  25. Sahebkar A, Serban C, Mikhailidis DP, Undas A, Lip GY, Muntner P, et al. Association between statin use and plasma D-dimer levels. Thromb Haemost. 2015;114(09):546–57.

  26. Kabaklić A, Fras Z. Moderate-dose atorvastatin improves arterial endothelial function in patients with angina pectoris and normal coronary angiogram: a pilot study. Arch Med Sci. 2017;13(4):827–36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Katsiki N, Reiner Ž, Tedeschi Reiner E, Al-Rasadi K, Pirro M, Mikhailidis DP, et al. Improvement of endothelial function by pitavastatin: a meta-analysis. Expert Opin Pharmacother. 2018;19(3):279–86.

  28. Sahebkar A, Kotani K, Serban C, Ursoniu S, Mikhailidis DP, Jones SR, et al. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis. 2015;241(2):433–42.

  29. Derosa G, Maffioli P, Reiner Ž, Simental-Mendía LE, Sahebkar A. Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs. 2016;76(9):947–56.

    Article  CAS  PubMed  Google Scholar 

  30. Celermajer DS, Chow CK, Marijon E, Anstey NM, Woo KS. Cardiovascular disease in the develo** world: prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol. 2012;60(14):1207–16.

    Article  PubMed  Google Scholar 

  31. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Pouyan A, S, Erfanmanesh M. Is Interleukin-38 a key player cytokine in atherosclerosis immune gene therapy? Med Hypotheses. 2019;125:139–43.

  33. Kovanen PT. Mast cells as potential accelerators of human atherosclerosis—from early to late lesions. Int J Mol Sci. 2019;20(18):4479.

    Article  CAS  PubMed Central  Google Scholar 

  34. Mohajeri M, Kovanen PT, Bianconi V, Pirro M, Cicero AF, Sahebkar A. Mast cell tryptase–marker and maker of cardiovascular diseases. Pharmacol Ther. 2019;199:91–110.

    Article  CAS  PubMed  Google Scholar 

  35. Wezel A, Lagraauw HM, van der Velden D, de Jager SC, Quax PH, Kuiper J, et al. Mast cells mediate neutrophil recruitment during atherosclerotic plaque progression. Atherosclerosis. 2015;241(2):289–96.

  36. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med. 2007;13(6):719–24.

  37. Bot I (2007) Jager SCA de, Zernecke A, Lindstedt KA, Berkel TJC van, Weber C, et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein Eedeficient mice Circulation 115:2516–2525.

  38. Smith DD, Tan X, Raveendran VV, Tawfik O, Stechschulte DJ, Dileepan KN. Mast cell deficiency attenuates progression of atherosclerosis and hepatic steatosis in apolipoprotein E-null mice. Am J Phys Heart Circ Phys. 2012;302(12):H2612–21.

    CAS  Google Scholar 

  39. • Kritikou E, Depuydt MAC, de Vries MR, Mulder KE, Govaert AM, Smit MD, et al. Flow Cytometry-based characterization of mast cells in human atherosclerosis. Cells. 2019;8(4). https://doi.org/10.3390/cells8040334. This study revealed a strong relationship between the presence of IgE and mast cells activation in human atherosclerosis plaques.

  40. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11(5):373–84.

    Article  CAS  PubMed  Google Scholar 

  41. Lee CC, Avalos AM, Ploegh HL. Accessory molecules for toll-like receptors and their function. Nat Rev Immunol. 2012;12(3):168.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Verstrepen L, Bekaert T, Chau T-L, Tavernier J, Chariot A, Beyaert R. TLR-4, IL-1R and TNF-R signaling to NF-κB: variations on a common theme. Cell Mol Life Sci. 2008;65(19):2964–78.

    Article  CAS  PubMed  Google Scholar 

  43. Wijnand K, Cheng C, Pasterkamp G, Duckers HJ. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis. 2010;209(2):314–20.

    Article  CAS  Google Scholar 

  44. Pasterkamp G, Van Keulen J, De Kleijn D. Role of toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Investig. 2004;34(5):328–34.

    Article  CAS  Google Scholar 

  45. Sandig H, Bulfone-Paus S. TLR signaling in mast cells: common and unique features. Front Immunol. 2012;3:185.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahbekar A. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res, 2018

  47. Gondokaryono SP, Ushio H, Niyonsaba F, Hara M, Takenaka H, Jayawardana ST, et al. The extra domain a of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol. 2007;82(3):657–65.

  48. Chansrichavala P, Chantharaksri U, Sritara P, Chaiyaroj SC. Atorvastatin attenuates TLR4-mediated NF-[kappa] B activation in a MyD88-dependent pathway. Asian Pac J Allergy Immunol. 2009;27(1):49–57.

    CAS  PubMed  Google Scholar 

  49. Shen D-Z, **n S-L, Chen C, Liu T. Effect of atorvastatin on expression of TLR4 and NF-κB p65 in atherosclerotic rabbits. Asian Pac J Trop Med. 2013;6(6):493–6.

    Article  CAS  PubMed  Google Scholar 

  50. • Kapelouzou A, Giaglis S, Peroulis M, Katsimpoulas M, Moustardas P, Aravanis CV, et al. Overexpression of toll-like receptors 2, 3, 4, and 8 is correlated to the vascular atherosclerotic process in the hyperlipidemic rabbit model: the effect of statin treatment. J Vasc Res. 2017;54(3):156–69. Fluvastatin treatment significantly decreased the progression of atherosclerosis and reduced inflammation via toll-like receptors downregulation.

  51. Albert MA, Glynn RJ, Wolfert RL, Ridker PM. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis. 2005;182(1):193–8.

    Article  CAS  PubMed  Google Scholar 

  52. Magrioti V, Kokotos G. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Expert Opin Ther Pat. 2010;20(1):1–18.

    Article  CAS  PubMed  Google Scholar 

  53. Katan M, Moon YP, Paik MC, Wolfert RL, Sacco RL, Elkind MS. Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the northern Manhattan study. PLoS One. 2014;9(1):e83393.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Tsimihodimos V, Karabina S-AP, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol. 2002;22(2):306–11.

  55. Kleinegris MC, ten Cate-Hoek AJ, Ten Cate H. Coagulation and the vessel wall in thrombosis and atherosclerosis. Pol Arch Med Wewn. 2012;122(11):557–66.

    CAS  PubMed  Google Scholar 

  56. Talreja J, Kabir MH, Filla B, M, Stechschulte DJ, Dileepan KN. Histamine induces toll-like receptor 2 and 4 expression in endothelial cells and enhances sensitivity to gram-positive and gram-negative bacterial cell wall components. Immunology. 2004;113(2):224–33.

  57. Roche C, Trimble E, Ennis M. Effect of in vivo and in vitro lovastatin treatment on mast cell activation. Int Arch Allergy Immunol. 1995;108(3):240–6.

    Article  CAS  PubMed  Google Scholar 

  58. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–30.

    Article  CAS  PubMed  Google Scholar 

  59. • Sahid MNA, Liu S, Kiyoi T, Maeyama K. Inhibition of the mevalonate pathway by simvastatin interferes with mast cell degranulation by disrupting the interaction between Rab27a and double C2 alpha proteins. Eur J Pharmacol. 2017;814:255–63. This study showed that simvastatin treatment suppress mast cell degranulation by inhibiting mevalonate pathway.

    Article  PubMed  CAS  Google Scholar 

  60. Kagami S-i, Kanari H, Suto A, Fujiwara M, Ikeda K, Hirose K, et al. HMG-CoA reductase inhibitor simvastatin inhibits proinflammatory cytokine production from murine mast cells. Int Arch Allergy Immunol. 2008;146(Suppl. 1):61–6.

  61. Fujimoto M, Oka T, Murata T, Hori M, Ozaki H. Fluvastatin inhibits mast cell degranulation without changing the cytoplasmic Ca2+ level. Eur J Pharmacol. 2009;602(2–3):432–8.

    Article  CAS  PubMed  Google Scholar 

  62. Kolawole EM, McLeod JJA, Ndaw V, Abebayehu D, Barnstein BO, Faber T, et al. Fluvastatin suppresses mast cell and basophil IgE responses: genotype-dependent effects. J Immunol. 2016;196(4):1461–70.

  63. Kolawole EM. The effect of fluvastatin on mast cell function: genotype dependence, 2014

  64. Virgolini I, Li S-R, Yang Q, Koller E, Sperr WR, Angelberger MLP, et al. Characterization of LDL and VLDL binding sites on human basophils and mast cells. Arterioscler Thromb Vasc Biol. 1995;15(1):17–26.

  65. Lindstedt K, Kokkonen J, Kovanen P. Soluble heparin proteoglycans released from stimulated mast cells induce uptake of low density lipoproteins by macrophages via scavenger receptor-mediated phagocytosis. J Lipid Res. 1992;33(1):65–75.

    CAS  PubMed  Google Scholar 

  66. Li S, Dudczak R, Koller E, Baghestanian M, Ghannadan M, Minar E, et al. Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils. Eur J Clin Pharmacol. 2003;59(7):507–16.

    Article  CAS  PubMed  Google Scholar 

  67. Di Salvo E, Ventura-Spagnolo E, Casciaro M, Navarra M, Gangemi S. IL-33/IL-31 axis: a potential inflammatory pathway. Mediat Inflamm. 2018;2018.

  68. Lu J, Kang J, Zhang C, Zhang X. The role of IL-33/ST2L signals in the immune cells. Immunol Lett. 2015;164(1):11–7.

    Article  CAS  PubMed  Google Scholar 

  69. Stankovic M, Ljujic B, Babic S, Maravic-Stojkovic V, Mitrovic S, Arsenijevic N, et al. IL-33/IL-33R in various types of carotid artery atherosclerotic lesions. Cytokine. 2019;120:242–50.

  70. Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine. 2007;40(3):216–25.

    Article  CAS  PubMed  Google Scholar 

  71. Rönnberg E, Ghaib A, Ceriol C, Enoksson M, Arock M, Säfholm J, Ekoff M, Nilsson G. Divergent effects of acute and prolonged interleukin 33 exposure on mast cell IgE-mediated functions. Frontiers in immunology 10. 2019

  72. Hsu C-L, Neilsen CV, Bryce PJ. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One. 2010;5(8):e11944.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Saluja R, Hawro T, Eberle J, Church M, Maurer M. Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and kit-independent pathways. J Biol Regul Homeost Agents. 2014;28(4):575–85.

    CAS  PubMed  Google Scholar 

  74. Taruselli M. The effect of statins on IL-33 mediated mast cell function. 2015

  75. Heo SH, Cho C-H, Kim HO, Jo YH, Yoon K-S, Lee JH, et al. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol. 2011;7(2):69–76.

  76. Jager NA, De Vries BMW, Hillebrands J-L, Harlaar NJ, Tio RA, Slart RH, et al. Distribution of matrix metalloproteinases in human atherosclerotic carotid plaques and their production by smooth muscle cells and macrophage subsets. Mol Imaging Biol. 2016;18(2):283–91.

  77. Kimata M, Ishizaki M, Tanaka H, Nagai H, Inagaki N. Production of matrix Metalloproteinases in human cultured mast cells: involvement of protein kinase C—mitogen activated protein kinase kinase—extracellular signal-regulated kinase pathway. Allergol Int. 2006;55(1):67–76.

    Article  CAS  PubMed  Google Scholar 

  78. Xu L, Cai Z, Yang F, Chen M. Activation-induced upregulation of MMP9 in mast cells is a positive feedback mediator for mast cell activation. Mol Med Rep. 2017;15(4):1759–64.

    Article  CAS  PubMed  Google Scholar 

  79. Silvello D, Narvaes LB, Albuquerque LC, Forgiarini LF, Meurer L, Martinelli NC, et al. Serum levels and polymorphisms of matrix metalloproteinases (MMPs) in carotid artery atherosclerosis: higher MMP-9 levels are associated with plaque vulnerability. Biomarkers. 2014;19(1):49–55.

  80. Sai L, YanQiu Z, DongMei C, YinJun L. Effect of rosuvastatin and benazepril on matrix metalloproteinase-2, matrix metalloproteinase-9 and leukotriene B4 of patients with acute myocardial infarction. Trop J Pharm Res. 2019;18(3):625–30.

    CAS  Google Scholar 

  81. Fujimoto S, Hartung D, Ohshima S, Edwards DS, Zhou J, Yalamanchili P, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol. 2008;52(23):1847–57.

Download references

Author information

Authors and Affiliations

  1. Department of hematology and blood bank, Tabas school of nursing, Birjand University of Medical Science, Birjand, Iran

    Hamideh Kouhpeikar

  2. Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Zahra Delbari

  3. Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, HU3 2JZ, UK

    Thozhukat Sathyapalan

  4. Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico

    Luis E. Simental-Mendía

  5. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

    Tannaz Jamialahmadi

  6. Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Tannaz Jamialahmadi

  7. Halal Research Center of IRI, FDA, Tehran, Iran

    Amirhossein Sahebkar

  8. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Amirhossein Sahebkar

  9. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

    Amirhossein Sahebkar

Authors
  1. Hamideh Kouhpeikar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zahra Delbari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thozhukat Sathyapalan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luis E. Simental-Mendía
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tannaz Jamialahmadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amirhossein Sahebkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amirhossein Sahebkar.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kouhpeikar, H., Delbari, Z., Sathyapalan, T. et al. The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review. Curr Atheroscler Rep 22, 19 (2020). https://doi.org/10.1007/s11883-020-00837-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-020-00837-9

Keywords

Search

Navigation